Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded...
-
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded...
-
23 April 2026, 15:00 CET ArcelorMittal today announces the publication of its first quarter 2026 sell-side analyst consensus figures. The consensus figures are based on analysts’ estimates recorded...
-
Report outlines encouraging progress with the ongoing transformation to world-class safety levels and a significant reduction in absolute carbon emissions1 23 April 2026, 08:30 CET ArcelorMittal...
-
[Ad hoc announcement pursuant to Art. 53 LR] This press release is also available in Français (pdf) and Deutsch (pdf) Follow today's event live09:30 CEST Investor call audio webcastFull details on...
-
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
-
Ad-hoc-Mitteilung gemäss Art. 53 KR. Dario Eklund übergibt die leitung nach geplanter übergangsphase Pratteln, Schweiz, 23. April 2026 – Santhera Pharmaceuticals (SIX: SANN) gibt die Ernennung von...
-
Ad hoc announcement pursuant to Art. 53 LR. Dario Eklund to hand over leadership following planned transition Pratteln, Switzerland, April 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces...
-
Konzernverkäufe stiegen in den ersten drei Monaten um +6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -5% und auf USD-Basis2 +9%) aufgrund hoher Nachfrage nach innovativen Medikamenten und...
-
Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and...